Komori
Ono Pharmaceutical (4528) · PolicyRestated

Balancing stable dividends with investment for future growth

First written in FY2016. 11 of 29 entries say "Advanced", first in FY2017. Latest entry: 2026-05-21.

29entries
11years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2021-Q1 – FY2022-Q2RestatedFY2025-H1 – 2026-05-212016: 220162017: 320172018: 320182019: 320192020: 220202021: 320212022: 420222023: 320232024: 320242025: 120252026: 22026
Same theme, other companies
Capital allocation policy balancing future investment and shareholder dividendsA theme 469 companies write about · 0 as a headwind · 471 as a tailwind

81 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 197 companies compared. The sentences above are computed from all 197.Comparing 200 of the theme's 473 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2025RestatedAnnual report

    「The Company regards returning profits to shareholders as one of its important management policies and pursues a progressive dividend policy of maintaining or increasing the annual dividend each year. Taking into account performance and various indicators for each fiscal year, the Company aims to pay dividends with a target payout ratio of approximately 40%.」

    The Company reaffirmed its progressive dividend policy and target payout ratio of approximately 40%. The annual dividend is forecast at ¥80 for the fiscal year ending March 2025 and ¥80 for the following fiscal year.
  2. FY2025-H1RestatedAnnual report

    「For the interim dividend for the 77th fiscal year (1 April 2024 to 31 March 2025), the Board of Directors resolved at its meeting held on 31 October 2024 to pay an interim dividend as follows to shareholders listed or recorded in the shareholder registry as of 30 September 2024. ① Total dividends: ¥18,791 million ② Dividend per share: ¥40.0」

    The Company resolved to pay an interim dividend of ¥40 per share for the fiscal year ending March 2025, reaffirming its policy of continuing to pay dividends.
  3. FY2024AdvancedAnnual report

    「From the next fiscal year onward, the Company will pursue a progressive dividend policy of maintaining or increasing the annual dividend each year. Taking into account performance and various indicators for each fiscal year, the Company aims to pay dividends with a target payout ratio of approximately 40%. The annual dividend for the next fiscal year is forecast at ¥80 per share.」

    The annual dividend increased to ¥80, and the Company explicitly stated its progressive dividend policy of maintaining or increasing the dividend, with a target payout ratio of approximately 40%. Of the maximum 19 million treasury shares, 18,732,400 were acquired and cancelled.
  4. FY2024-Q3AdvancedAnnual report

    「Total number of treasury shares acquired during the first nine months of the current consolidated fiscal year: 13,627,300 shares ③ Total acquisition cost: ¥37,244,178,150」

    Of the maximum 19 million shares and ¥50 billion approved for acquisition in July 2023, 13,627,300 shares were acquired for approximately ¥37.2 billion by the end of December, implementing the shareholder return measure.
  5. FY2024-Q2AdvancedAnnual report

    「② Total number of shares to be acquired: 19 million shares (maximum) / ③ Total acquisition cost: ¥50 billion (maximum) / ④ Acquisition period: 1 August 2023 to 22 March 2024 / Total number of treasury shares acquired during the first six months of the current consolidated fiscal year: 9,889,200 shares / Total acquisition cost: ¥27,183,823,500 / Dividends attributable to the first six months of the current consolidated fiscal year with an effective date after the end of the current second quarter consolidated accounting period: Common shares, ¥19,140 million, ¥40.0 per share」

    Of the maximum 19 million shares and ¥50 billion allocated for the treasury share acquisition, 9,889,200 shares were acquired for approximately ¥27.18 billion by the end of the first six months. The interim dividend was ¥40 per share, up from ¥33 in the first six months of the previous fiscal year.
  6. FY2024-Q1AdvancedAnnual report

    「On 25 July 2023, the Company resolved, by written resolution in lieu of a Board of Directors meeting pursuant to Article 370 of the Companies Act, to acquire treasury shares under Article 156 of the Companies Act as applied by replacing the relevant provisions pursuant to Article 165, Paragraph 3 of the Act. It also resolved to cancel treasury shares pursuant to Article 178 of the Companies Act. / Total number of shares to be acquired: 19 million shares (maximum) / Total acquisition cost: ¥50 billion (maximum) / Acquisition period: 1 August 2023 to 22 March 2024 / Planned action after acquisition: cancellation of all treasury shares acquired」

    As a shareholder return measure, the Company resolved to acquire up to 19 million treasury shares for up to ¥50 billion and cancel all shares acquired.
  7. FY2023Increase in annual dividendAnnual report

    「For the fiscal year, the Company paid an ordinary dividend of ¥33 per share as an interim dividend and an ordinary dividend of ¥37 per share as a year-end dividend. Including the interim and year-end dividends, the annual dividend was ¥70 per share.」

    The annual dividend increased from ¥56 in the previous fiscal year to ¥70, reflecting the policy of prioritizing stable dividends while distributing returns in line with performance.
  8. FY2023-Q2Increase in the interim dividendAnnual report

    「Six months ended 30 September 2022 31 October 2022 Board of Directors Common shares ¥16,115 million ¥33.0 30 September 2022 1 December 2022」

    The interim dividend for the fiscal year ending March 2023 was ¥33.0 per share, up from ¥28.0 in the same period of the previous year.
  9. FY2023-Q1AchievedAnnual report

    「Pursuant to a resolution of the Board of Directors meeting held on 6 April 2022, the Company cancelled treasury shares on 28 April 2022 in accordance with Article 178 of the Companies Act. / (2) Total number of shares cancelled: 10,916,200 shares (2.07% of the total number of issued shares before cancellation) / (3) Cancellation date: 28 April 2022 23 June 2022 Annual General Meeting of Shareholders Common shares ¥13,671 million ¥28.0 31 March 2022 24 June 2022」

    The Company cancelled the 10,916,200 treasury shares acquired in fiscal 2021 on 28 April 2022. The year-end dividend for the fiscal year ended March 2022 was ¥28.0 per share, up from ¥27.5 in the previous year.
  10. FY2022AdvancedAnnual report

    「Regarding dividends from surplus for the fiscal year, the Company paid an interim ordinary dividend of ¥28 per share and a year-end ordinary dividend of ¥28 per share. The total annual dividend, combining the interim and year-end dividends, was ¥56 per share. / During the fiscal year, the Company acquired 10,916,200 treasury shares for a total cost of ¥30,000 million.」

    The annual dividend increased from ¥50 per share in the previous fiscal year to ¥56, and the Company acquired 10,916,200 shares for ¥30 billion under the repurchase plan covering up to 11 million shares for up to ¥30 billion.
  11. FY2022-Q3AdvancedAnnual report

    「② Total number of shares to be acquired: 11 million shares (maximum) / ③ Total acquisition cost: ¥30 billion (maximum) / ④ Acquisition period: 29 November 2021 to 28 April 2022 / ⑥ Planned action after acquisition: cancellation of all acquired treasury shares / Total number of treasury shares acquired during the nine months ended 31 December: 5,724,700 shares / Total acquisition cost: ¥15,455,413,750」

    As part of measures to improve capital efficiency and return profits to shareholders, the Company resolved to repurchase up to 11 million shares for a total of up to ¥30 billion and cancel all acquired shares, and had acquired 5,724,700 shares by the end of the quarter. The interim dividend had also increased to ¥28.0 per share.
  12. FY2022-Q2Increase in the interim dividendAnnual report

    「Six months ended 30 September 2021 1 November 2021 Board of Directors Common shares ¥13,977 million ¥28.0 30 September 2021 1 December 2021」

    The interim dividend for the fiscal year ending March 2022 was ¥28.0 per share, up from ¥22.5 in the same period of the previous year.
  13. FY2022-Q1Increase in the year-end dividendAnnual report

    「17 June 2021 Annual General Meeting of Shareholders Common shares ¥13,726 million ¥27.5 31 March 2021 18 June 2021」

    The Company paid a year-end dividend of ¥27.5 per share for the fiscal year ended March 2021, totaling ¥13,726 million. The dividend increased from ¥22.5 per share in the same period of the previous year.
  14. FY2021Increase in annual dividendAnnual report

    「Regarding dividends from surplus for the fiscal year, the Company paid an interim ordinary dividend of ¥22.50 per share and a year-end ordinary dividend of ¥27.50 per share. The total annual dividend, combining the interim and year-end dividends, was ¥50 per share.」

    Under its policy of prioritizing stable dividends, the annual dividend increased from ¥45 per share in the previous fiscal year to ¥50.
  15. FY2021-Q2RestatedAnnual report

    「Regarding the interim dividend for the 73rd fiscal year (1 April 2020 to 31 March 2021), the Board of Directors resolved at its meeting held on 29 October 2020 to pay an interim dividend as follows to shareholders listed or recorded in the shareholder registry as of 30 September 2020. ① Total dividend ¥11,232 million ② Dividend per share ¥22.5」

    The Company resolved to pay an interim dividend of ¥22.5 per share for the fiscal year ending March 2021, reconfirming its policy of continuing to pay dividends.
  16. FY2021-Q1RestatedAnnual report

    「18 June 2020 Annual General Meeting of Shareholders Common shares ¥11,230 million ¥22.5 31 March 2020 19 June 2020」

    The Company paid a year-end dividend of ¥22.5 per share for the fiscal year ended March 2020, totaling ¥11,230 million, reconfirming its policy of continuing to pay dividends.
  17. FY2020-Q2AchievedAnnual report

    「During the six months ended 30 September, the total number of treasury shares acquired was 15,000,000, at a total acquisition cost of ¥29,576,153,400. / (Note) The Company cancelled 15,000,000 treasury shares on 31 October 2019.」

    Regarding the repurchase of up to 15 million shares for a total of up to ¥30 billion resolved on 30 May 2019, the Company completed the acquisition of 15 million shares and cancelled all acquired shares on 31 October 2019.
  18. FY2020-Q1AdvancedAnnual report

    「During the three months ended 30 June, the total number of treasury shares acquired was 5,132,400, at a total acquisition cost of ¥9,999,822,700.」

    Regarding the treasury share repurchase resolved on 30 May 2019, the Company acquired 5,132,400 shares, worth approximately ¥10 billion, in the first quarter, implementing measures to return profits to shareholders and improve capital efficiency.
  19. FY2019AdvancedAnnual report

    「Total number of shares to be acquired: 15 million shares (maximum) / Total acquisition cost: ¥30 billion (maximum) / Acquisition period: 31 May 2019 to 30 September 2019 / Planned action after acquisition: cancellation of all acquired treasury shares」

    Pursuant to the resolution of 30 May 2019, the Company resolved to repurchase up to 15 million shares for a total of up to ¥30 billion and cancel all acquired shares, adding measures to return profits to shareholders and improve capital efficiency.
  20. FY2019-Q2RestatedAnnual report

    「Six months ended 30 September 2018 1 November 2018 Board of Directors Common shares ¥11,568 million ¥22.5 30 September 2018 3 December 2018」

    The Company resolved to pay an interim dividend of ¥22.5 per share, totaling ¥11,568 million, reconfirming its policy of continuing to pay dividends.
  21. FY2018RestatedAnnual report

    「Regarding dividends from surplus for the fiscal year, the Company paid an interim ordinary dividend of ¥25 per share, including a ¥5 commemorative dividend marking its 300th anniversary, and a year-end ordinary dividend of ¥20 per share. The total annual dividend, combining the interim and year-end dividends, was ¥45 per share.」

    The Company paid an annual dividend of ¥45 per share, including the commemorative dividend, under its policy of prioritizing stable dividends.
  22. FY2018-Q3AchievedAnnual report

    「(3) Total number of treasury shares acquired 15,896,100 shares / (4) Total acquisition cost ¥38,766,145,700 / (2) Total number of treasury shares cancelled 45,896,100 shares / (3) Cancellation date 31 October 2017」

    The approved treasury share repurchase was completed with the acquisition of 15,896,100 shares for approximately ¥38.8 billion, and 45,896,100 treasury shares were cancelled on 31 October 2017.
  23. FY2018-Q2AdvancedAnnual report

    「During the six months ended 30 September, the total number of treasury shares acquired was 15,896,100, at a total acquisition cost of ¥38,766,145,700. / The per-share dividend resolved by the Board of Directors on 6 November 2017 included a ¥5 commemorative dividend marking the Company's 300th anniversary.」

    Regarding the treasury share repurchase resolved in the previous fiscal year, the Company acquired approximately 15.89 million shares, worth approximately ¥38.8 billion, during the six months, implementing its shareholder return policy. The ¥25 interim dividend per share included a ¥5 commemorative dividend marking the Company's 300th anniversary.
  24. FY2018-Q1AdvancedAnnual report

    「(2) Total number of shares acquired 9,252,800 shares / (3) Total acquisition cost ¥22,497,327,550 / (4) Acquisition period 14 June 2017 to 30 June 2017」

    Regarding the treasury share repurchase resolved in the previous fiscal year, the Company acquired 9,252,800 shares, worth approximately ¥22.5 billion, in the first quarter.
  25. FY2017AdvancedAnnual report

    「At a Board of Directors meeting held on 13 June 2017, the Company resolved matters relating to the repurchase of treasury shares and also resolved to cancel treasury shares. The total number of shares to be repurchased was capped at 20 million, with the total purchase price capped at ¥50 billion, and the Company planned to cancel all repurchased shares and 30 million treasury shares already held.」

    In addition to its policy of stable dividends and investment for growth, the Company resolved to repurchase up to 20 million shares for a total of up to ¥50 billion to improve capital efficiency and return profits to shareholders, and to cancel the shares, including those already held.
  26. FY2017-Q2RestatedAnnual report

    「Regarding the interim dividend for the 69th fiscal year (1 April 2016 to 31 March 2017), the Board of Directors resolved at its meeting held on 7 November 2016 to pay an interim dividend as follows to shareholders listed or recorded in the shareholder registry as of 30 September 2016. / ① Total dividend ¥10,602 million / ② Dividend per share ¥20」

    The Company resolved to pay a total interim dividend of ¥10,602 million, or ¥20 per share, demonstrating its continued payment of dividends.
  27. FY2016First statedAnnual report

    「Regarding profit allocation, we regard returning profits to shareholders as one of management's key policies and intend to distribute earnings in line with performance while prioritizing the continuation of stable dividends. Regarding the use of retained earnings, we intend to actively apply them to future business development, including research and development of new drugs in Japan and overseas, partnerships with biotechnology ventures, and the in-licensing of new drug candidate compounds to mitigate development risks.」

    The Company prioritizes stable dividends and performance-linked distributions in returning profits to shareholders, and plans to allocate retained earnings to research and development, partnerships and the in-licensing of compounds.
Moved together

"Expansion of the development pipeline and continued launches of new drugs" moved the same way as this thread, in the same document, in 14 of its 29 moves.

1414131187★123456
  1. ★This thread
  2. 1Expansion of the development pipeline and continued launches of new drugs14×
  3. 2In-Licensing Promising New Drug Candidate Compounds and Accelerating Clinical Trials14×
  4. 3Expansion of Opdivo’s indications and progress in international development and sales13×
  5. 4Global business expansion and international launches11×
  6. 5Strengthening the R&D organization by incorporating the world's most advanced expertise and technologies8×
  7. 6Drug Discovery Collaborations with Universities, Research Institutions and Biotech Ventures7×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Ono Pharmaceutical's next results are scheduled for 2026-10-29. Read the earnings preview It last moved in the General Meetings of Shareholders of 2026-05-21: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Balancing stable dividends with investment for future growth | ONO PHARMACEUTICAL CO.,LTD. (4528) | Komori